Tag: Chemotherapy
Addition of Atezolizumab May Aid in Metastatic Urothelial Cancer
Phase 3 trial shows prolonged progression-free survival for atezolizumab plus platinum-based chemo
UGN-101 Active in Chemoablation of Upper Tract Urothelial Cancer
Fifty-nine percent of patients had complete response at four to six weeks after initial therapy
Smoking Tied to Inferior Survival in Acute Myeloid Leukemia
Smoking associated with inferior survival among patients receiving intensive chemotherapy for AML
Polypharmacy Ups Postchemo Hospitalization Risk in Seniors
Findings seen in older patients with prostate, breast, and lung cancers
Low Muscle Mass, Density Linked to Shorter Survival in Lymphoma
13 percent of DLBCL patients had LMM, LMD, which was associated with shorter OS and PFS
Chemo Ups Disease-Free Survival in Upper Tract Urothelial Cancer
Gemcitabine-platinum combination therapy tied to improved survival after nephroureterectomy
Adding Pembrolizumab May Up Response in Triple-Negative Breast Cancer
Pathological complete response rate higher with pembrolizumab plus neoadjuvant chemotherapy
Dasatinib Tops Imatinib for Ph+ Acute Lymphoblastic Leukemia
Four-year cumulative risk of any relapse lower for dasatinib in the context of intensive chemotherapy
One-Cycle BE500P Seems Safe for High-Risk Early Testicular Cancer
Malignant recurrence rate was 1.3 percent at two years for one-cycle BE500P in high-risk early-stage disease
Adverse Events Decreased With Proton Chemoradiotherapy
Relative risks lower for 90-day adverse events of at least grade 3 and 2 compared with photon therapy
